StockNews.com Upgrades Minerva Neurosciences (NASDAQ:NERV) to “Hold”

StockNews.com upgraded shares of Minerva Neurosciences (NASDAQ:NERV) from a sell rating to a hold rating in a research note published on Thursday.

Separately, HC Wainwright decreased their price target on shares of Minerva Neurosciences from $11.00 to $7.00 and set a neutral rating on the stock in a research report on Thursday.

Minerva Neurosciences Price Performance

Shares of NASDAQ NERV traded up $0.02 during trading hours on Thursday, hitting $2.37. 15,458 shares of the company’s stock were exchanged, compared to its average volume of 17,188. The company’s 50-day moving average price is $2.66 and its 200-day moving average price is $5.30. Minerva Neurosciences has a 1-year low of $2.29 and a 1-year high of $13.49.

Minerva Neurosciences (NASDAQ:NERV) last posted its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($1.19) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.31). Research analysts anticipate that Minerva Neurosciences will post -3.57 EPS for the current year.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.